Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma

HAYWARD, Calif.--(BUSINESS WIRE)-- Aarvik Therapeutics, a biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that its collaboration partner ArriVent BioPharma, Inc. has exercised the option to exclusively license the collaboration program.

As part of the research collaboration agreement entered into between Aarvik and ArriVent on December 21, 2021, Aarvik has been responsible for discovery and preclinical development of a novel ADC molecule that relies on the unique modular platform developed by Aarvik. ArriVent will be responsible for clinical development and commercialization. Aarvik has received an upfront payment, research funding and an opt-in payment, and is eligible to receive contingent development and commercial milestones, plus royalties.

“Aarvik has shown that it can combine the most advanced protein engineering technologies with deep ADC drug development expertise to enable next-generation, best-in-class oncology therapies,” said Jagath Reddy Junutula, PhD, Co-founder, President and CEO of Aarvik Therapeutics. “Aarvik will continue to pursue previously hard-to-treat indications through the power of its novel multi-targeting platforms.”

“We are delighted to see Aarvik reach this significant milestone,” said Sachdev Sidhu, PhD, Co-founder and Board member of Aarvik Therapeutics. “This provides further validation and underscores the power and potential of Aarvik antibody platforms and deep protein engineering capabilities.”

About Aarvik Therapeutics

Aarvik Therapeutics combines unique, proprietary modular platforms with multiple target mechanisms to develop novel molecules with an improved therapeutic index for oncology targets. Backed by the extensive scientific, research, development and business expertise of its founders, Board, SAB and team members, Aarvik Therapeutics is applying its vision and passion to create transformational benefit for cancer patients.

For additional information, visit www.aarviktx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240815164343/en/

Media Contact
Pradeep Fernandes
[email protected]

Source: Aarvik Therapeutics

You May Also Be Interested In

• AM Best Affirms Credit Ratings of The Travelers Companies, Inc. and Subsidiaries
• Reuters NEXT Gulf leadership summit to return with Abu Dhabi Department of Economic Development as exclusive host city partner for next three years
• Starcloud Raises $250 Million at $2.3 Billion Valuation to Scale AI with Orbital Data Centers